WebMar 22, 2024 · BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a cell membrane phospholipid (clinical formulation BXQ-350).Due to the presumed mechanism of action of BXQ-350, Bexion … WebApply to this Phase 1 & 2 clinical trial treating Acute Myeloid Leukemia (AML), Allogeneic Stem Cell Transplantation. Get access to cutting edge treatment via Siremadlin. View duration, location, compensation, and staffing details. Siremadlin (HDM201) for Acute Myeloid Leukemia.
BXQ-350AD: A Study of BXQ-350 in Children With Newly …
WebOct 4, 2024 · Company Drug/Device Medical Condition Status Trials Authorized Bexion Pharmaceuticals BXQ-350 Newly diagnosed stage 4 metastatic colorectal cancer IND approved by the FDA Pharmazz centhaquine Hypovolemic shock IND approved by the FDA Everest Medicines SPR206 (EVER206) Multi-drug resistant gram-negative bacterial … WebJan 11, 2024 · In the trial, all participants will receive BXQ-350 by intravenous (IV) infusion plus standard of care doses of mFOLFOX and bevacizumab. Stage 1 of the study will be … ecommunity plus
Bexion doses first participant in trial of colorectal carcinoma therapy
WebJan 10, 2024 · BXQ-350, an "S1P Activator", has demonstrated pre-clinical antitumor effects in vitro and in vivo, particularly in colorectal, brain and other solid tumors. Bexion has completed two single... WebOfficial Title A Phase Ib/II Placebo Controlled, Double Blinded Study on the Efficacy and Safety of BXQ-350 in Combination with mFOLFOX7 and Bevacizumab in Newly Diagnosed Metastatic Colorectal Carcinoma Details WebBXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid … ecommunity outreach pontiac